OBiO Biotechnology (Shanghai) Corp. Ltd., (“OBiO” or “the Company”), announced it will be attending the American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting to be held virtually from May 11-14, 2021.
Feel free to join the OBiO virtual booth livestream on May 11 and 13 from 10:30 a.m. to 12:00 p.m. EST, to learn more about gene and cell therapy market access in China and OBiO’s role as a CDMO to help biotech speed up their commercialization worldwide. Dr. Guodong Jia, General Manager of OBiO, will exchange and share insights on gene therapy product research and manufacturing with other global industry professionals around the world.
To access the meeting, please visit :
For OBiO’s pre-show listing, please visit :
OBiO Technology (Shanghai) Corp., Ltd. is a biopharmaceutical CDMO/CMO company founded in 2013 which currently has more than 380 employees, over a quarter of whom are educated to PhD and M.Sc level. In 2016, OBiO built its gene therapy manufacturing platform meeting regulatory requirements in China, Europe and the United States. The GMP platform offers holistic CDMO services across plasmid, adeno-associated virus, lentivirus, adenovirus, oncolytic viruses, and cell therapy products for scientists, research facilities, medical institutions, and pharmaceutical companies. In 2020, OBiO initiated construction of a 80,000sqm OBiO Intelli-M GMP manufacturing site in Shanghai to satisfy explosive global demand for gene therapy products. OBiO strives to become the leading gene therapy CDMO and a trustworthy partner for global biopharmaceuticals and biotech companies.
